A phase I/II study of MM-111, a novel bispecific antibody that targets the ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer.
M. J. Higgins
Consultant or Advisory Role - Merrimack (U)
N. Y. Gabrail
No relevant relationships to disclose
K. Miller
Research Funding - Merrimack
S. V. Agresta
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
S. Sharma
No relevant relationships to disclose
C. McDonagh
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
J. Murray
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
K. Andreas
Employment or Leadership Position - Merrimack
S. Frye
Employment or Leadership Position - Merrimack
V. M. Moyo
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
C. Niyikiza
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
P. D. Ryan
No relevant relationships to disclose